Background
==========

Anaphylaxis is a 'severe, life-threatening generalised or systemic hypersensitivity reaction' \[[@B1],[@B2]\]. Several working definitions of anaphylaxis have been formulated to aid clinical diagnosis and management \[[@B3]-[@B6]\]. The most well-known of these is the consensus clinical definition proposed by Sampson et al., which involved representatives of a number of international allergy organisations, including the European Academy of Allergy and Clinical Immunology (EAACI) \[[@B7]\].

Whilst useful clinically, definitions in which the presumption of exposure to a known trigger substantially increase the likelihood of making the diagnosis are of limited value for epidemiological investigations. Hence, current estimates of the epidemiology of anaphylaxis will be subject to uncertainty depending on the case definition used \[[@B8]\]. Reliably establishing the epidemiology of anaphylaxis is further complicated by the fact that it is a relatively uncommon condition, which is acute in onset and transient, rendering it difficult to mount prospective investigations \[[@B9]\]. Investigators may therefore need to use less than ideal study designs, which further results in the possibility of generating biased estimates.

Notwithstanding these inherent challenges, there is a need to improve our understanding of the epidemiology of anaphylaxis in order to inform deliberations on, amongst other things, the overall disease burden posed by the condition, obtain etiological insights, risk stratification and prognosis.

Epidemiological measures of particular interest for anaphylaxis therefore include measures of incidence and prevalence, risk factors, and risk of recurrence and death. The following epidemiological definitions proposed by Last, and adapted for anaphylaxis will be employed in this review: \[[@B10]\].

Incidence
---------

The number of new cases of anaphylaxis that occur during a given period in a defined population. Incidence will be studied as:

• *Incidence rate:* The number of new cases of anaphylaxis that occur during a defined period per unit person-time.

• *Cumulative incidence*: The number of new cases of anaphylaxis that occur during a given period per the population at risk.

Prevalence
----------

The proportion of a defined population known to have experienced anaphylaxis. Care is required in defining the appropriate denominator. This epidemiological measure will be further divided into:

• *Point prevalence:* the proportion of the population that has experienced anaphylaxis at a specific time.

• *Period prevalence:* the proportion of the population that has experienced anaphylaxis during a given period.

• *Lifetime prevalence:* the proportion of the population that at some point in their life will have experienced anaphylaxis.

Case fatality rate
------------------

The proportion of cases of anaphylaxis that proves fatal (usually defined within a time period). This is also sometimes known as the case fatality ratio.

Other aspects of interest concern features of persons who experience anaphylaxis, temporal relationships, and the factors that lead to its development and recurrence.

The EAACI is in the process of developing the *EAACI Guideline for Food Allergy and Anaphylaxis*, and this systematic review is one of seven inter-linked evidence syntheses that are being undertaken in order to provide a state-of-the-art synopsis of the current evidence base in relation to epidemiology, prevention, diagnosis and clinical management and impact on quality of life, which will be used to inform clinical recommendations.

Aims
====

The aims of this systematic review will be to:

• Understand and describe the epidemiology of anaphylaxis, i.e. frequency, risk factors and outcomes of anaphylaxis

• Describe how these characteristics vary by person, place and time.

Methods
=======

Search strategy
---------------

A highly sensitive search strategy has been designed to retrieve all articles combining the concepts of anaphylaxis and epidemiology from electronic bibliographic databases. We have conceptualised the search to incorporate three elements, as shown in Figure [1](#F1){ref-type="fig"}: Conceptualisation of systematic review of the epidemiology of anaphylaxis.

![Conceptualisation of systematic review on the epidemiology of anaphylaxis.](2045-7022-3-9-1){#F1}

To retrieve systematic reviews, we will use the systematic review filter developed at McMaster University Health Information Research Unit \[[@B11]\]. We have also adapted the search filter from York University Centre for Reviews and Dissemination \[[@B12]\] to retrieve incidence, prevalence and other characteristics describing the epidemiology of anaphylaxis. Similarly, we also applied the McMaster filter for prognosis studies \[[@B13]\].

The following databases will be searched:

• MEDLINE (OVID)

• Embase (OVID)

• CINAHL (Ebscohost)

• ISI Web of Science (Thomson Web of Knowledge).

The search strategy has been devised on OVID MEDLINE and then adapted for the other databases (see Additional file [1](#S1){ref-type="supplementary-material"}). In all cases the databases will be searched from 1 January 2000 to 30 September 2012, and will be limited to Europe based on the definition provided by the Organization for Economic Co-operation and Development (OECD) \[[@B14]\]. The countries covered by this restriction include Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom. All references will be imported into an EndNote Library and tagged with the name of the database. Searches will be limited to literature from 2000 onwards; because we want to understand and describe the contemporary epidemiology of anaphylaxis.

Additional references will be located through searching the references cited by the identified studies, and unpublished work and research in progress will be identified through discussion with experts in the field. We will invite experts who are active in the field from a range of disciplines and geography to comment on our search strategy, and the list of included studies.

There will be no language restrictions and, where possible, all literature will be translated.

Inclusion criteria for study design
-----------------------------------

• Systematic reviews +/-meta-analyses

• Cohort studies

• Cross-sectional studies

• Case-control studies

• Routine healthcare studies

These study designs were chosen to ensure that the highest levels of evidence were pooled based on the aims of this review \[[@B15]\].

Exclusion criteria for study design
-----------------------------------

• Reviews, discussion papers, non-research letters and editorials

• Case studies and case series

• Animal studies

Study selection
---------------

The titles of the retrieved articles will be checked independently by two reviewers according to the above selection criteria and categorised as: included, not included and unsure. For those papers in the unsure category we will retrieve the abstract and re-categorise as above after further discussion on them. Any discrepancies will be resolved by consensus and if necessary a third reviewer will be consulted to arbitrate. Full text copies of potentially relevant studies will be obtained and their eligibility for inclusion independently assessed by two reviewers. Studies that do not fulfil all of the inclusion criteria will be excluded.

Risk of bias assessment strategy
--------------------------------

Risk of bias assessments will be independently carried out on each study by two reviewers using the relevant version of the Critical Appraisal Skills Programme (CASP) quality assessment tool for systematic reviews \[[@B16]\], cohort studies \[[@B17]\] and case-control studies \[[@B18]\], which involves an assessment of both internal and external validity \[[@B19]\]. Similarly, we will use the Effective Public Health Practice Project Quality Assessment Tool (EPHPP) for assessing other forms of quantitative studies such as cohort analyses, cross-sectional studies and routine healthcare studies \[[@B20]\]. An overall grading and grading for the various components of each study (e.g. the appropriateness of the study design for the research question, the risk of selection bias, exposure measurement, and outcome assessment) will be given to each study. Any discrepancies will be resolved by discussion or, if agreement could not be reached, by arbitration by a third reviewer.

Analysis, data synthesis and reporting
--------------------------------------

Data will be independently extracted onto a customised data extraction sheet by two reviewers, and any discrepancies will be resolved by discussion or, if agreement could not be reached, by arbitration by a third reviewer.

A descriptive summary with data tables will be produced to summarise the literature. If clinically and statistically appropriate, meta-analysis using either fixed-effector random-effects modeling will be undertaken using methods suggested by Agresti and Coul \[[@B21]\]. A narrative synthesis of the data will also be undertaken.

This review has been registered with the International Prospective Register of Systematic Reviews (PROSPERO) and has registration number CRD42013003702 allocated to it. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist will be used to guide the reporting of the systematic review \[[@B22]\].

Discussion
==========

The occurrence of anaphylaxis can have a profound effect on the quality of life of the sufferer and their family. The risk of recurrence may be high and some attacks prove fatal, sometimes despite immediate, on-site treatment with epinephrine. Successfully identifying those at greatest risk of an initial attack, and a recurrence, could reduce morbidity, but this has proved difficult in practice using demographic and clinical markers. Secondary analyses of routine sources of data have proved helpful in describing the epidemiology of anaphylaxis though the estimates generated would be considered more reliable if the data could be validated and linked across primary and secondary care sectors. Such validation work needs to be prioritized. This review will aid in providing some estimates of the frequency of anaphylaxis in Europe. At present, the best epidemiological estimates appear to come from North-West Europe, but more information is needed from Southern and Eastern Europe.
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